Abstract
Literature publications (up to September 2006) concerning the synthesis of ω-phosphinyl-α-amino acids and their development towards use as therapeutic agents are reviewed. General and asymmetric methodologies for the preparation of straight-chain examples are described, including AP3-7 modulators of glutamate-responsive excitatory amino acid (EAA) receptors (i.e. ionotropic NMDA-, and metabotropic GrpIII mGlu-receptors), and the glutamate synthetase inhibitor phosphinothricin. Focusing primarily on the development of methods for introducing phosphonate and aminocarboxylate functions to the appropriate scaffold, approaches to conformationally constrained ω-phosphinyl-α-amino acids are also investigated, along with their relevance to the development of therapeutic regimens towards neurodegenerative disorders.
Current Organic Chemistry
Title: ω -Phosphinyl-α -Amino Acids: Synthesis, and Development towards Use as Therapeutic Agents
Volume: 11 Issue: 18
Author(s): Nick J. Wardle, S. W. Annie Bligh and Harry R. Hudson
Affiliation:
Abstract: Literature publications (up to September 2006) concerning the synthesis of ω-phosphinyl-α-amino acids and their development towards use as therapeutic agents are reviewed. General and asymmetric methodologies for the preparation of straight-chain examples are described, including AP3-7 modulators of glutamate-responsive excitatory amino acid (EAA) receptors (i.e. ionotropic NMDA-, and metabotropic GrpIII mGlu-receptors), and the glutamate synthetase inhibitor phosphinothricin. Focusing primarily on the development of methods for introducing phosphonate and aminocarboxylate functions to the appropriate scaffold, approaches to conformationally constrained ω-phosphinyl-α-amino acids are also investigated, along with their relevance to the development of therapeutic regimens towards neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Wardle J. Nick, Annie Bligh W. S. and Hudson R. Harry, ω -Phosphinyl-α -Amino Acids: Synthesis, and Development towards Use as Therapeutic Agents, Current Organic Chemistry 2007; 11 (18) . https://dx.doi.org/10.2174/138527207783221200
DOI https://dx.doi.org/10.2174/138527207783221200 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Editorial [ Neurodegenerative Disorders: From Molecules to Man (Part 2) Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito ]
CNS & Neurological Disorders - Drug Targets Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
CNS & Neurological Disorders - Drug Targets Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms and Pathophysiology of Necrotic Cell Death
Current Molecular Medicine Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation
CNS & Neurological Disorders - Drug Targets To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Ethical Implications for Clinical Practice and Future Research in “At Risk” Individuals
Current Pharmaceutical Design Role of Autophagy in Parkinson’s Disease
Current Medicinal Chemistry Structures Behind the Amyloid Aggregation of α-Synuclein: An NMR based Approach
Current Protein & Peptide Science Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson’s Disease
Current Neuropharmacology Perylenebisimide-based Fluorescent Chemosensors for Selective Detection of Zn2+ in Aqueous Solution
Letters in Organic Chemistry Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism